Study of AND017 for low-risk myelodysplastic syndrome
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests an experimental drug called AND017 for people with a certain type of myelodysplastic syndrome (MDS) that is low-risk and not linked to a chromosome 5 deletion. The goal is to see if AND017 can help improve low red blood cell counts (anemia) and reduce or avoid the need for blood transfusions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary MDS that is very low, low, or intermediate risk (not high risk).
- Your MDS is not caused by a deletion in chromosome 5 (non-5q).
- Your average hemoglobin level (without a blood transfusion) is between 6.0 and 10.0 g/dL, measured at least a week apart.
- You have either not needed any red blood cell transfusions in the last 16 weeks, or you have had only a few (1 to 7 units) in that time.
- Your EPO (a hormone that tells your body to make red blood cells) level is 500 mU/mL or lower.
- Your platelet count is at least 30,000 and your neutrophil count is at least 800, and your liver and kidney function are within safe limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug, TAK-226, for people with lower-risk myelodysplastic syndromes (MDS) who have anemia. The study aims to see if the drug can help improve blood counts and reduce the need for red blood cell transfusions.
This study tests a new drug called elritercept for people with myelodysplastic syndromes (MDS) who have low blood counts and need regular blood transfusions. The drug aims to boost red blood cell production and reduce or eliminate the need for transfusions, which can improve energy and quality of life.
This trial is testing a new medicine called HS-20106 to see if it can improve anemia (low red blood cells) for people with certain types of MDS. If it works, it might reduce the need for blood transfusions.
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
This Phase 1/2 study tests luspatercept combined with another approach in people with low-risk myelodysplastic syndrome (MDS) who are not responding to or cannot use ESA (a common anemia treatment). It may help improve anemia (low hemoglobin), reduce transfusions, and control the disease if you fit the specific criteria.
This study tests a new therapy called MNV-201 for people with low-risk myelodysplastic syndromes (MDS) who have anemia and need regular blood transfusions. The goal is to see if this treatment can help reduce or stop the need for transfusions.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.